Tectonic Therapeutic, Inc. (TECX)
22.05
+0.16
(+0.73%)
USD |
NASDAQ |
Nov 10, 16:00
22.05
0.00 (0.00%)
After-Hours: 20:00
Tectonic Therapeutic Enterprise Value : 186.39M for Nov. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 09, 2026 | 186.39M |
| November 06, 2026 | 162.35M |
| November 05, 2026 | 138.88M |
| November 04, 2026 | 155.81M |
| November 03, 2026 | 130.42M |
| November 02, 2026 | 130.42M |
| October 30, 2026 | 145.81M |
| October 29, 2026 | 159.66M |
| October 28, 2026 | 160.81M |
| October 27, 2026 | 156.58M |
| October 26, 2026 | 149.08M |
| October 23, 2026 | 151.38M |
| October 22, 2026 | 171.00M |
| October 21, 2026 | 185.43M |
| October 20, 2026 | 185.14M |
| October 19, 2026 | 172.16M |
| October 16, 2026 | 162.54M |
| October 15, 2026 | 175.04M |
| October 14, 2026 | 168.50M |
| October 13, 2026 | 175.24M |
| October 12, 2026 | 195.24M |
| October 09, 2026 | 214.09M |
| October 08, 2026 | 202.93M |
| October 07, 2026 | 202.17M |
| October 06, 2026 | 196.39M |
| Date | Value |
|---|---|
| October 05, 2026 | 209.86M |
| October 02, 2026 | 198.90M |
| October 01, 2026 | 201.40M |
| September 30, 2026 | 213.32M |
| September 29, 2026 | 226.28M |
| September 28, 2026 | 229.55M |
| September 25, 2026 | 232.63M |
| September 24, 2026 | 241.28M |
| September 23, 2026 | 257.83M |
| September 22, 2026 | 287.06M |
| September 21, 2026 | 289.56M |
| September 18, 2026 | 296.68M |
| September 17, 2026 | 300.72M |
| September 16, 2026 | 314.19M |
| September 15, 2026 | 325.73M |
| September 14, 2026 | 348.81M |
| September 11, 2026 | 336.11M |
| September 10, 2026 | 327.65M |
| September 09, 2026 | 363.62M |
| September 08, 2026 | 362.08M |
| September 04, 2026 | 368.81M |
| September 03, 2026 | 352.85M |
| September 02, 2026 | 361.70M |
| September 01, 2026 | 377.85M |
| August 31, 2026 | 353.23M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.946B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 176.34M |
| Savara, Inc. | 894.64M |
| Vericel Corp. | 2.903B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.35M |
| Total Expenses (Quarterly) | 21.35M |
| EPS Diluted (Quarterly) | -1.083 |
| Earnings Yield | -21.00% |
| Normalized Earnings Yield | -21.00 |